216 related articles for article (PubMed ID: 31054897)
41. [Plasmacytoid urothelial carcinoma of the urinary bladder. A study of 7 cases].
Gaafar A; Garmendia M; de Miguel E; Velasco V; Ugalde A; Bilbao FJ; de Petris G; López JI
Actas Urol Esp; 2008 Sep; 32(8):806-10. PubMed ID: 19013979
[TBL] [Abstract][Full Text] [Related]
42. Plasmacytoid urothelial carcinoma of the bladder: histological and clinical features of 5 cases.
Fritsche HM; Burger M; Denzinger S; Legal W; Goebell PJ; Hartmann A
J Urol; 2008 Nov; 180(5):1923-7. PubMed ID: 18801525
[TBL] [Abstract][Full Text] [Related]
43. Rare Plasmacytoid Urothelial Carcinoma of the Bladder: Two Case Reports.
Devrim T; Atac F; Altunkaya C; Ozbek A; Ozdemir G; Eryol M
Urol J; 2019 Feb; 16(1):86-88. PubMed ID: 29781067
[TBL] [Abstract][Full Text] [Related]
44. [Urinary cytology. Possibilities, limitations and the future].
Zaak D; Tritschler S; Knuechel R; Vom Dorp F; Hakenberg OW; Hautmann S; Rübben H
Urologe A; 2006 Sep; 45 Suppl 4():97-101. PubMed ID: 16821054
[TBL] [Abstract][Full Text] [Related]
45. Loss of MTAP Expression by Immunohistochemistry Is a Surrogate Marker for Homozygous 9p21.3 Deletion in Urothelial Carcinoma.
Vlajnic T; Chijioke O; Roma L; Savic Prince S; Zellweger T; Rentsch CA; Bubendorf L
Mod Pathol; 2024 Jun; 37(6):100495. PubMed ID: 38641323
[TBL] [Abstract][Full Text] [Related]
46. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
47. Recurrent urothelial tumors following surgery for transitional cell carcinoma of the upper urinary tract.
Strong DW; Pearse HD
Cancer; 1976 Nov; 38(5):2173-83. PubMed ID: 991130
[TBL] [Abstract][Full Text] [Related]
48. Plasmacytoid urothelial carcinoma of renal pelvis with positive zinc finger E-box-binding homeobox 1: a case report.
Takada-Owada A; Nozawa Y; Onozaki M; Noda S; Jamiyan T; Tokura Y; Nakazato Y; Kamai T; Ishida K
Diagn Pathol; 2020 Oct; 15(1):124. PubMed ID: 33032610
[TBL] [Abstract][Full Text] [Related]
49. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study.
Samaratunga H; Khoo K
Histopathology; 2004 Jul; 45(1):55-64. PubMed ID: 15228444
[TBL] [Abstract][Full Text] [Related]
50. HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder.
Kim B; Kim G; Song B; Lee C; Park JH; Moon KC
Dis Markers; 2016; 2016():8463731. PubMed ID: 27034533
[TBL] [Abstract][Full Text] [Related]
51. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
52. [Clinical and pathologic characteristics of small cell neuroendocrine carcinoma of urinary tract].
Guo AT; Chen W; Wei LX
Zhonghua Bing Li Xue Za Zhi; 2012 Nov; 41(11):747-51. PubMed ID: 23302335
[TBL] [Abstract][Full Text] [Related]
53. Plasmacytoid urothelial carcinoma: detailed analysis of morphology with clinicopathologic correlation in 17 cases.
Nigwekar P; Tamboli P; Amin MB; Osunkoya AO; Ben-Dor D; Amin MB
Am J Surg Pathol; 2009 Mar; 33(3):417-24. PubMed ID: 19011563
[TBL] [Abstract][Full Text] [Related]
54. [Expression of transferrin receptor on transitional cell cancer].
Tomita Y; Nishiyama T; Sato S; Fujiwara M
Hinyokika Kiyo; 1991 Jan; 37(1):11-6. PubMed ID: 2011963
[TBL] [Abstract][Full Text] [Related]
55. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
Palsgrove DN; Taheri D; Springer SU; Cowan M; Guner G; Mendoza Rodriguez MA; Rodriguez Pena MDC; Wang Y; Kinde I; Ricardo BFP; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Hum Pathol; 2019 Mar; 85():1-9. PubMed ID: 30447301
[TBL] [Abstract][Full Text] [Related]
56. Serous Carcinoma Mimicking Primary Urothelial Carcinoma on Clinical Evaluation and Pathology: A Potential Diagnostic Pitfall.
Mirsadraei L; Hodkoff A; Jones K; Shabaik A; Kader AK; Saenz CC; Montironi R; Tacha DE; Fadare O; Hansel DE
Arch Pathol Lab Med; 2018 Feb; 142(2):168-177. PubMed ID: 28795841
[TBL] [Abstract][Full Text] [Related]
57. [Pancreatic secretory trypsin inhibitor in urothelial cancer].
Tashiro K; Torii S; Iwamuro S; Ohishi Y; Hasegawa N; Kawashima Y; Mochizuki A; Yoshigoe H; Wada T; Machida T
Hinyokika Kiyo; 1989 Oct; 35(10):1659-63. PubMed ID: 2610172
[TBL] [Abstract][Full Text] [Related]
58. Bilateral ureteral inverted papilloma with synchronous transitional cell tumor of the bladder.
Hoekx L; Wyndaele JJ
Acta Urol Belg; 1998 Oct; 66(3):17-9. PubMed ID: 9864872
[TBL] [Abstract][Full Text] [Related]
59. Urothelial carcinoma of the bladder and the upper tract: disparate twins.
Green DA; Rink M; Xylinas E; Matin SF; Stenzl A; Roupret M; Karakiewicz PI; Scherr DS; Shariat SF
J Urol; 2013 Apr; 189(4):1214-21. PubMed ID: 23023150
[TBL] [Abstract][Full Text] [Related]
60. High expression of Chitinase 3-like-1 is an unfavorable prognostic factor in urothelial carcinoma of upper urinary tract and urinary bladder.
Lee YE; Chan TC; Tian YF; Liang PI; Shiue YL; Chen YS; He HL
Urol Oncol; 2019 May; 37(5):299.e7-299.e18. PubMed ID: 30660494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
